Literature DB >> 7529765

Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant alpha and beta polypeptide chains.

S Arimilli1, C Cardoso, P Mukku, V Baichwal, B Nag.   

Abstract

Major histocompatibility complex (MHC) class II molecules are cell surface heterodimeric glycoproteins consisting of one alpha and one beta polypeptide chain of similar size. These molecules play a critical role in immune recognition by displaying processed antigens to CD4-positive T helper cells. Several attempts to express the MHC class II molecules by recombinant methods in various systems resulted in either failure or poor recovery of the intact heterodimer. The present study describes our successful effort to refold and reconstitute HLA DR2 heterodimer from individually expressed alpha and beta polypeptide chains lacking the transmembrane hydrophobic regions in Escherichia coli, in the presence of an immunodominant epitope analog from human myelin basic protein (b-MBP(83-102)Y83). The reconstituted DR2 heterodimer complex was selectively purified from unfolded alpha and beta chains using heterodimer-specific monoclonal antibody (L243) coupled to a solid support. The detection of two polypeptide chains in the purified refolded DR2-peptide complex preparations was accomplished by Western blot analysis and enzyme-linked immunosorbent assay using heterodimer- and chain-specific polyclonal antibodies, and the presence of equimolar amounts of both alpha chain and beta chain in the reconstituted complex preparation was confirmed by a double label experiment. The quantitation of the bound peptide in complex preparation was measured by incubating two chains in the presence of 125I-labeled peptide. An increase in the yield of refolded and reconstituted DR2-peptide complexes was observed with increasing peptide concentration in the reaction mixture. Finally, the functional activity of the reconstituted DR2 complexes was measured by their ability to stimulate gamma-interferon production by SS8T cloned T cells in an antigen-specific and dose-dependent manner. These results demonstrate that biologically active complexes of human DR2.b-MBP (83-102)Y83 can be prepared by proper folding of human leukocyte antigen DR2 alpha and beta chains in the presence of antigenic peptide. The yield of such DR2 heterodimers with bound peptide is several thousand-fold higher over native DR2 purified from transformed B cells. Since purified MHC class II-peptide complexes have been shown to prevent autoimmune diseases in various animal models, reconstituted heterodimer complexes may have significant clinical relevance in antigen-specific treatment of various autoimmune diseases. In addition, such complexes with increased yield will provide better understanding of the trimolecular interactions between MHC-peptide and T cell receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529765     DOI: 10.1074/jbc.270.2.971

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

2.  Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity.

Authors:  Jianya Y Huan; Roberto Meza-Romero; Jeffery L Mooney; Yuan K Chou; David M Edwards; Cathleen Rich; Jason M Link; Arthur A Vandenbark; Dennis N Bourdette; Hans-Peter Bächinger; Gregory G Burrows
Journal:  J Chem Technol Biotechnol       Date:  2004-10-12       Impact factor: 3.174

3.  Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

Authors:  P Chames; S E Hufton; P G Coulie; B Uchanska-Ziegler; H R Hoogenboom
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.

Authors:  Olesya Chornoguz; Alexei Gapeev; Michael C O'Neill; Suzanne Ostrand-Rosenberg
Journal:  Mol Cell Proteomics       Date:  2012-08-31       Impact factor: 5.911

5.  Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease.

Authors:  J Huan; R Meza-Romero; J L Mooney; A A Vandenbark; H Offner; G G Burrows
Journal:  Mucosal Immunol       Date:  2010-08-25       Impact factor: 7.313

6.  Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.

Authors:  Monica Moro; Virginia Cecconi; Chiara Martinoli; Eliana Dallegno; Barbara Giabbai; Massimo Degano; Nicholas Glaichenhaus; Maria Pia Protti; Paolo Dellabona; Giulia Casorati
Journal:  BMC Immunol       Date:  2005-12-05       Impact factor: 3.615

Review 7.  Opportunities and Challenges for Antibodies against Intracellular Antigens.

Authors:  Xiaofeng Yang; Shenxia Xie; Xiaomei Yang; Juan C Cueva; Xiaoqiong Hou; Zhuoran Tang; Hua Yao; Fengzhen Mo; Shihua Yin; Aiqun Liu; Xiaoling Lu
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

8.  Functional recombinant MHC class II molecules and high-throughput peptide-binding assays.

Authors:  Sune Justesen; Mikkel Harndahl; Kasper Lamberth; Lise-Lotte B Nielsen; Søren Buus
Journal:  Immunome Res       Date:  2009-05-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.